Grau Juan J, Mesía Ricard, de la Iglesia-Vicente Maria, Williams Estrelania S, Taberna Miren, Caballero Miguel, Larque Ana-Belen, de la Oliva Jorge, Cordón-Cardo Carlos, Domingo-Domenech Josep
Department of Medical Oncology, University of Barcelona, IDIBAPS, Hospital Clinic Barcelona, Barcelona, Spain.
Oncology. 2016;90(5):267-72. doi: 10.1159/000445118. Epub 2016 Apr 15.
Patients with head and neck squamous cell carcinoma (HNSCC) present different responses to chemotherapy and radiotherapy. One explanation may be the differences in the individual rates of stem cell-like cells.
We included patients with HNSCC and tumor progression or relapse. Tumor samples were obtained before and after primary chemotherapy, and immunohistochemical analyses were performed for CD44, HLA class I (HLA-I), pancytokeratin, and phosphorylated epidermal growth factor receptor (p-EGFR). Differences in expression between the first and second specimens were assessed.
Expression between the first and second specimens varied as follows: CD44 increased by 14.67% (95% confidence interval, CI: 6.94 to 22.40; p < 0.01); HLA-I decreased by 16.72% (95% CI: -23.87 to -9.47; p < 0.01); pancytokeratin decreased by 24.91% (95% CI: -32.8 to -17.7; p < 0.01), and p-EFGR expression decreased by 12.30% (95% CI: -20.61 to -3.98; p < 0.005).
Among patients with HNSCC, there is an enrichment of cells with stem-like markers in relapsed tumors when compared with the primary tumor. This finding should be considered when developing treatment strategies.
头颈部鳞状细胞癌（HNSCC）患者对化疗和放疗呈现出不同的反应。一种解释可能是干细胞样细胞的个体比例存在差异。
我们纳入了HNSCC且有肿瘤进展或复发的患者。在初次化疗前后获取肿瘤样本，并对CD44、I类人白细胞抗原（HLA-I）、全细胞角蛋白和磷酸化表皮生长因子受体（p-EGFR）进行免疫组化分析。评估第一次和第二次样本之间的表达差异。
第一次和第二次样本之间的表达变化如下：CD44增加了14.67%（95%置信区间，CI：6.94至22.40；p<0.01）；HLA-I降低了16.72%（95%CI：-23.87至-9.47；p<0.01）；全细胞角蛋白降低了24.91%（95%CI：-32.8至-17.7；p<0.01），p-EFGR表达降低了12.30%（95%CI：-20.61至-3.98；p<0.005）。
在HNSCC患者中，与原发肿瘤相比，复发肿瘤中具有干细胞样标志物的细胞有所富集。在制定治疗策略时应考虑这一发现。
